English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In his companion editorial, Dr. Coit lauds the final analysis of the first Multicenter Selective Lymphadenectomy Trial (MSLT-I), reported recently in the New England Journal of Medicine, saying that it “has provided clinicians with invaluable very high quality information to interpret and use in the management of their melanoma patients”.1 However, he expresses concern about “how the authors have presented this information to the readers”. The planning and conduct of MSLT-1 was a mammoth project, and the fact that the final report was not publishable until 20 years after the first of the 2001 trial patients was randomized highlights not only the scale of the undertaking but also the dedication and commitment of clinicians, trial personnel, and patients around the world to its successful completion, when 10 years of follow-up had been achieved for all trial participants. The mass of data collected in MSLT-I over the 20-year period was large, making it impossible to report and discuss all the results in a single journal publication. However, we can reassure Dr. Coit and others that hitherto unreported trial data will be presented in subsequent publications.

Sentinel Lymph Node Biopsy for Melanoma: A Plea to Let the Data be Heard